Progress in immunotherapy targeting PD-1/PD-L1 for lung cancer / 中国实用内科杂志

Lung cancer is the leading cause of cancer-related mortality with high malignancy. In recent years, a major breakthrough has been made in immunotherapy targeting PD-1/PD-L1 for lung cancer, which altered the traditional therapeutic pattern of lung cancer and heralded the dawn of the new immune era. This paper reviewed the application of immune checkpoint blockers in the subtypes of lung cancer, immune-related adverse events, the selection of potential biomarkers, and the exploration of resistance mechanisms.